What is Injectable Drug Delivery Devices?
Injectable Drug Delivery devices comprise of self-injectors, needle-free, auto injectors and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need of any medical assistance.
What is the market for Global Injectable Drug Delivery Devices?
Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026.
What are the drivers for Global Injectable Drug Delivery Devices?
The major drivers driving the demand for Injectable Drug Delivery Devices are the rising incidences of chronic conditions, for instance the cancer, diabetes and cardiovascular disorders among others, an increase in the demand for self-injectors, rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.
For more information on Injectable Drug Delivery Devices Market, click here @ https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market
What are the key players operating in Global Injectable Drug Delivery Devices?
Some of the key market players operating in the Injectable Drug Delivery Devices market includes Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.
What regions has the highest share in Injectable Drug Delivery Devices market?
North America is expected to dominate the overall Injectable Drug Delivery Devices market during the forecast period, 2021 to 2026. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives in order to improve awareness about the chronic conditions and the rise in healthcare spending.
Recent Developmental Activities in Injectable Drug Delivery Devices Market:
· On August 21, 2021, Zydus Cadila’s needle-free, plasmid DNA Covid vaccine had received the Drug Controller General of India (DCGI) approval.
· On November 13, 2019, Stevanato and Duoject had entered auto-injector collaboration for manufacturing and promoting the emergency use ‘Maverick’ auto-injector.
· On October 21, 2019, Becton Dickinson and Company, a leading global medical technology company had announced the launch of BD Intevia™ 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.
Request for sample pages of Injectable Drug Delivery Devices Competitive Analysis@ https://www.delveinsight.com/sample-request/injectable-drug-delivery-devices-market